Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Share-based Compensation (2016 - 2022)

Historic Share-based Compensation for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to $1.1 million.

  • RedHill Biopharma's Share-based Compensation fell 3936.0% to $1.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.7 million, marking a year-over-year decrease of 4442.81%. This contributed to the annual value of $665000.0 for FY2024, which is 5962.36% down from last year.
  • According to the latest figures from Q4 2022, RedHill Biopharma's Share-based Compensation is $1.1 million, which was down 3936.0% from $1.6 million recorded in Q3 2022.
  • RedHill Biopharma's Share-based Compensation's 5-year high stood at $5.3 million during Q2 2021, with a 5-year trough of $468000.0 in Q3 2018.
  • For the 5-year period, RedHill Biopharma's Share-based Compensation averaged around $1.3 million, with its median value being $839000.0 (2018).
  • As far as peak fluctuations go, RedHill Biopharma's Share-based Compensation surged by 74654.9% in 2021, and later crashed by 8828.21% in 2022.
  • RedHill Biopharma's Share-based Compensation (Quarter) stood at $671000.0 in 2018, then increased by 11.62% to $749000.0 in 2019, then soared by 44.46% to $1.1 million in 2020, then surged by 73.29% to $1.9 million in 2021, then plummeted by 39.36% to $1.1 million in 2022.
  • Its Share-based Compensation was $1.1 million in Q4 2022, compared to $1.6 million in Q3 2022 and $618000.0 in Q2 2022.